We randomly assigned 4589 healthy nulliparous women who were 13 to 21 weeks pregnant to receive daily treatment with either 2 g of elemental calcium or placebo for the remainder of their pregnancies. Surveillance for preeclampsia was conducted by personnel unaware of treatment-group assignments, using standaradized measurements of blood pressure and urinary protein excretion at uniformly scheduled prenatal visits, protocols for monitoring these measurements during the hospitalization for delivery, and reviews of medical records of unscsheduled outpatient visits and all hospitalizations. Calcium supplementation did not significantly reduce the incidence or severity of preeclampsia or delay its onset. Preeclampsia occurred in 158 of the 2295 women in the calcium group (6.9 percent) and 168 of the 2294 women in the placebo group (7.3 percent) (relative risk, 0.94; 95 percent confidence interval, 0.76 to 1.16). There were no significant differences between the two groups in the prevalence of pregnancy-associated hypertension without preeclampsia (15.3 percent vs. 17.3 percent) or of all hypertensive disorders (22.2 percent vs. 24.6 percent). The mean systolic and diastolic blood pressures during pregnancy were similar in both groups. Calcium did not reduce the numbers of preterm deliveries, small-for-gestational age births, or fetal and neonatal deaths; nor did it increase urolithiasis during pregnancy.

National Institute of Health (NIH)
Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)
Intramural Research (Z01)
Project #
Application #
Study Section
Epidemiology and Biometry Training Committee (EB)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
United States
Zip Code
England, Lucinda J; Grauman, Alyssa; Qian, Cong et al. (2007) Misclassification of maternal smoking status and its effects on an epidemiologic study of pregnancy outcomes. Nicotine Tob Res 9:1005-13
Tjoa, May Lee; Levine, Richard J; Karumanchi, S Ananth (2007) Angiogenic factors and preeclampsia. Front Biosci 12:2395-402
Rana, Sarosh; Karumanchi, S Ananth; Levine, Richard J et al. (2007) Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension 50:137-42
Levine, Richard J; Lam, Chun; Qian, Cong et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 355:992-1005
Levine, Richard J; Qian, Cong; Maynard, Sharon E et al. (2006) Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol 194:1034-41
Bdolah, Yuval; Palomaki, Glenn E; Yaron, Yuval et al. (2006) Circulating angiogenic proteins in trisomy 13. Am J Obstet Gynecol 194:239-45
Signore, Caroline; Mills, James L; Qian, Cong et al. (2006) Circulating angiogenic factors and placental abruption. Obstet Gynecol 108:338-44
Levine, Richard J; Thadhani, Ravi; Qian, Cong et al. (2005) Urinary placental growth factor and risk of preeclampsia. JAMA 293:77-85
Levine, Richard J; Karumanchi, S Ananth (2005) Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol 48:372-86
Levine, Richard J; Qian, Cong; Leshane, Erik S et al. (2004) Two-stage elevation of cell-free fetal DNA in maternal sera before onset of preeclampsia. Am J Obstet Gynecol 190:707-13

Showing the most recent 10 out of 19 publications